S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Solaray Enters Longevity Market With Targeted Eight-Product System

Seventy-five percent of the aging process is dictated by lifestyle rather than genetics, according to research. To address this, supplement manufacturer Solaray is launching UNLIMIT, an eight-formula system designed to support cellular energy, muscle integrity, and bone density through targeted, science-backed ingredients rather than trend-driven formulations.

Solaray Enters Longevity Market With Targeted Eight-Product System
Photo: Bio & News

The new product line centers on three core formulas: Creatine + MBP, designed to bolster muscle recovery and bone mineral density; a clinically dosed NMN supplement; and Liposomal NAD+, which utilizes advanced delivery systems to improve absorption and support cellular energy. By focusing on these specific biological markers, the company aims to move beyond generic wellness toward a measurable, consistent approach to long-term physical performance.

Rachel Kilroy, senior director of product innovation, noted that the system is intended to simplify the often-confusing longevity category. Beyond the primary trio, the collection includes five additional targeted supplements—Liposomal Glutathione, PEAK ATP, Spermidine, Fisetin, and NADH—allowing users to tailor their routines. Every product is manufactured at Solaray's GMP-certified facility in Utah, adhering to the brand's long-standing mandate for triple-testing identity, purity, and potency.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!